Comparison

CTX-712 European Partner

Item no. HY-144875-100mg
Manufacturer MedChem Express
CASRN 2144751-78-8
Amount 100 mg
Quantity options 100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category
Type Chemicals
Specific against other
Purity 98.60
Formula C19H17FN8O2
Citations [1]Akinori Yoda, et al. CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation. Blood. (2021) 205–206
[2]Zhen Qin, et al. Development of Cdc2-like Kinase 2 Inhibitors: Achievements and Future Directions. J Med Chem. 2021 Sep 23;64(18):13191-13211.
Smiles CC1=NC2=NC=C(C3=C4C(OC)=NC=NN4C=C3)C=C2N1CC5=NN=C([C@H](F)C)O5
ECLASS 10.1 32160000
ECLASS 11.0 32160000
UNSPSC 12000000
Shipping condition Room temperature
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
Cancer-Kinase/protease
Manufacturer - Targets
CDK
Shipping Temperature
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Molecular Weight
408.39
Product Description
CTX-712 is an orally effective CLK 2 inhibitor, with an IC50 of 1.4 nM, showing anti-tumor activity[1][2].
Manufacturer - Research Area
Cancer
Solubility
DMSO : 25 mg/mL (ultrasonic)
Manufacturer - Pathway
Cell Cycle/DNA Damage
Isoform
CLK
Clinical information
Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close